Jump to content
Wikipedia The Free Encyclopedia

Brenipatide

From Wikipedia, the free encyclopedia
(Redirected from LY-3537031)

Pharmaceutical compound
Brenipatide
Clinical data
Other namesLY-3537031; LY3537031
Routes of
administration 		Subcutaneous injection [1] [2]
Drug class GLP-1 receptor agonist; GIP receptor agonist
Identifiers
  • D-Tyrosyl-2-methylalanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-L-leucyl-L-α-aspartyl-L-lysyl-N6-[N-(19-carboxy-1-oxononadecyl) -L-γ-glutamyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-2-[2-(2-aminoethoxy)ethoxy]acetyl] -L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-α-methyl-L-tyrosyl-L-leucyl-L-isoleucyl-L-alanylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide
CAS Number
PubChem SID
UNII
Chemical and physical data
Formula C228H354N46O72
Molar mass 4891.590g·mol−1

Brenipatide (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name; developmental code name LY-3537031) is a dual agonist of glucagon-like peptide-1 (GLP-1) receptors and gastric inhibitory polypeptide (GIP) receptors.

Brenipatide is under development by Eli Lilly and Company for the treatment of alcoholism, bipolar disorder, asthma, smoking withdrawal, cardiovascular disorders, liver disorders, metabolic disorders, and obesity.[1] [3] [4] [2]

It is taken by subcutaneous injection once per month.[1] [4] [2] The drug has a longer elimination half-life than tirzepatide or retatrutide.[2]

As of December 2025, it was in phase 3 clinical trials for alcoholism and bipolar disorder, phase 2 trials for asthma and smoking withdrawal, and phase 1 trials for cardiovascular disorders, liver disorders, metabolic disorders, and obesity.[1] [4]

See also

[edit ]

References

[edit ]
  1. 1 2 3 4 "Brenipatide - Eli Lily and Company". AdisInsight. 22 December 2025. Retrieved 13 January 2026.
  2. 1 2 3 4 Østergaard S (December 2025). "Advancing obesity treatments through innovations in the design and manufacturing of therapeutic peptides". Expert Opinion on Drug Discovery: 1–24. doi:10.1080/17460441.2025.2601113. PMID 41381216. Brenipatide is a once-monthly dual-acting peptide from Eli Lilly that targets GLP-1R and GIPR (Table 1) and is currently in a Phase 3 clinical trial for moderate-to-severe alcohol use disorder (NCT07219966). Although it has a single C20 diacid, it exhibits a longer half-life than tirzepatide and retatrutide, likely because of a backbone optimized for stability against enzymatic degradation through a Trp to αMe-Tyr substitution.
  3. ↑ "Delving into the Latest Updates on Brenipatide with Synapse". Synapse. 11 March 2026. Retrieved 16 March 2026.
  4. 1 2 3 "Brenipatide Drug Profile". Ozmosi. Retrieved 16 March 2026.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

AltStyle によって変換されたページ (->オリジナル) /